Repetitive transcranial magnetic stimulation alleviates glial activation through suppressing HMGB1/TLR4 pathway in a rat model of Parkinson’s disease - Molecular Biology Reports

Background Repetitive transcranial magnetic stimulation (rTMS) has been demonstrated to be effective in Parkinson’s disease (PD), but whether rTMS treatment has a relieving effect on neuroinflammation remains to be investigated. In this article, we explored the effects of rTMS on forelimb use asymmetry and neuroinflammation-related mechanisms in a 6-hydroxydopamine (6-OHDA)-induced PD rat model. Methods and results Rats in the 6-OHDA+rTMS group received 10 Hz rTMS daily for 4 weeks. Behavioral tests (the cylinder test) were performed at the 3rd and 7th weeks after the operation. Astrocyte and microglia activation and protein levels of tyrosine hydroxylase(TH), high-mobility group box 1(HMGB1) and toll-like receptors 4(TLR4) were investigated by immunohistochemistry and Western blot analyses, respectively. After 4 weeks of treatment, forelimb use asymmetry was ameliorated in the 6-OHDA+rTMS group. Consistent with the behavioral tests, rTMS increased TH in the substantia nigra (SN) and the striatum of PD rats. High glial activation and HMGB1/TLR4 expression in the SN and the striatum were observed in the 6-OHDA group, while rTMS alleviated these changes. Conclusions This study showed that rTMS might be a promising method for alleviating neuroinflammation in PD rat models, and the effects might be mediated through the downregulation of the HMGB1/TLR4 pathway.

Εξάρτηση από ουσίες: Τι είναι, πώς αναγνωρίζεται και ποιες είναι οι λύσεις - Zougla

Η μείωση της επιθυμίας για χρήση ουσιών (craving) είναι η βασική θετική επίδραση του rTMS, η οποία διαμεσολαβείται από την εφαρμογή υψηλής συχνότητας διεγερτικά sessions στον αριστερό προμετωπιαίο φλοιό.

Bienvenue sur le site de la Miviludes | MIVILUDES